NEW YORK, June 23, 2022 /PRNewswire/ -- As per Zion Market Research study, The global scleroderma diagnostics and therapeutics market was approximately USD 2232.5 million in 2021 and is anticipated to reach nearly USD 4127.6 million by 2028, with a compound annual growth rate (CAGR) of about 9.2 percent over the forecast period.
Key Industry Insights & Finding of the Scleroderma Diagnostics and Therapeutics Market Reports:
As per the analysis shared by our research analyst, the Scleroderma Diagnostics and Therapeutics Market is expected to grow annually at a CAGR of around 9.2 % (2022-2028).
Through the primary research, it was established that the Scleroderma Diagnostics and Therapeutics Market was valued approximately USD 2232.5 Million in 2021 and is projected to reach to roughly USD 4127.6 Million by 2028.
Major factors such as favorable reimbursement policies, heavy investment in R&D and drug development, and well-established healthcare infrastructure are boosting the growth of the market in this region.
The growing prevalence of the disease and technological advancement in the field of medical devices are also propelling the growth of the market in this region.
Europe is anticipated to hold the second-most position in the market owing to an increase in initiatives and proactive awareness regarding the diagnostics for scleroderma.
Zion Market Research published the latest report titled as "Scleroderma Diagnostics And Therapeutics Market By Diagnostic Test Type (Blood Tests, Imaging Techniques, Skin Biopsy, Pulmonary Function Tests, And Electrocardiogram & Echocardiogram), By Indication (Systemic Scleroderma And Localized Scleroderma), By Drug Class (Prostacyclin Analogues, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors – PHA, Immunosuppressors, Analgesics, Calcium Channel Blockers, And Others), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028." into their research database.
Scleroderma Diagnostics and Therapeutics Market : Overview
Scleroderma is an autoimmune disease wherein healthy tissue is substituted with thick, dense, fibrous tissue. It is a chronic, albeit rare, condition. The immune system normally aids in the body's defense against sickness and infection. The immune system in scleroderma patients causes other cells to create excessive collagen. This excess collagen builds up in the organs and skin, causing hardness and thickness similar to the process of scarring. While scleroderma has no cure, therapy can help to alleviate symptoms, reduce progression, and enhance the quality of life. Scleroderma can impact several other body parts, such as the gastrointestinal system, joints, muscles, blood vessels, kidneys, and lungs, in addition to the skin. Scleroderma can be life-threatening in its most severe forms.
Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/scleroderma-diagnostics-and-therapeutics-market
Our Free Sample Report Includes:
2022 Updated Report Introduction, Overview, and In-depth industry analysis
COVID-19 Pandemic Outbreak Impact Analysis Included
180 + Pages Research Report (Inclusion of Updated Research)
Provide Chapter-wise guidance on Request
2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
Includes Updated List of tables & figures
Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
Zion Market Research methodology
Scleroderma Diagnostics and Therapeutics Market : Growth Drivers
Growing prevalence of scleroderma is fostering the growth of the market.
In developed as well as developing countries, the prevalence of scleroderma is growing at a rapid rate. This condition affects between 75,000 to 100,000 persons in the United States, the majority of whom are females between the ages of 30 to 50. Twins and family members of people with scleroderma or even other autoimmune connective tissue illnesses like lupus are at an increased risk of developing the condition. Scleroderma can affect children, although the condition affects them differently than it does adults. Such a huge burden of disease has led to increase in awareness and need for diagnosis of the disease. This is ultimately driving the market growth. In addition to this, favorable reimbursement policies, well-developed health infrastructure, and growing necessity for developed diagnostic techniques are some of the key factors that are boosting the growth of the market for scleroderma diagnostics and therapeutics.
Scleroderma Diagnostics and Therapeutics Market : Restraints
High cost associated with scleroderma diagnostic and treatment is likely to hamper the market growth.
The multiorgan nature of systemic sclerosis necessitates long-term monitoring and a variety of approaches to patient management. As a result, it's no surprise that systemic sclerosis is one of the most expensive rheumatic illnesses, with patients using more healthcare dollars per year than their age and sex-matched colleagues with inflammatory myopathies, psoriatic arthritis, and/or RA. Additionally, some of the direct costs for patients with systemic sclerosis include acute-care hospitalization, assistive devices, medications, diagnostic tests as well as visits to healthcare professionals. Thus, the financial cost of systemic sclerosis is substantial, and disease & health conditions have a significant influence on the economic burden thereby impeding the growth of the global scleroderma diagnostics and therapeutics market. In addition to this, factors such as low penetration of the market in underdeveloped countries, adverse effects associated with the drugs, and low spending power in rural areas are also hampering the market growth.
Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/scleroderma-diagnostics-and-therapeutics-market
Global Scleroderma Diagnostics and Therapeutics Market : Opportunities
Growing focus on development of innovative methods is estimated to drive the market during the forecast period.
Systemic sclerosis is a multifaceted autoimmune disease with a wide range of symptoms and degrees of internal organ damage. All consequences have a substantial influence on the patient's quality of life as well as morbidity and death rates. As a result, there is a growing interest in novel ways of assessing, diagnosing, and monitoring organ involvement. In addition to this, there is an increase in investment in R&D activities by major players for the development of new and effective treatments. Major players are also focusing on the completion of clinical trials for the drugs and looking forward to the approval of the drug for the treatment of scleroderma. All such factors coupled with technological advancements including the implementation of artificial intelligence and internet of things in the field of medical devices are anticipated to generate numerous opportunities for the growth of the global scleroderma diagnostics and therapeutics market during the forecast period.
Global Scleroderma Diagnostics and Therapeutics Market : Challenges
Strict regulations for the approval of drugs and diagnostic devices for scleroderma may act as a challenge to the market growth.
By far there are very less approved drugs for the treatment of scleroderma. Scleroderma is a rare disease and its diagnosis is also challenging. The vague clinical presentation of scleroderma might make diagnosis difficult, resulting in a delayed diagnosis. This also interferes in the development of drugs that can be effectively used to treat the disease. The lack of sufficient data on the efficacy and safety of the drugs leads to the failure of clinical trials. The regulatory bodies across different countries have imposed strict regulations for the approval of drugs and diagnostic devices in order to have appropriate diagnosis and treatment of the disease. This may act as a major challenge to the growth of the market.
Global Scleroderma Diagnostics and Therapeutics Market : Segmentation
The global scleroderma diagnostic and therapeutics market is categorized based on diagnostic test type, indication, drug class, and region.
The diagnostic test type segment comprises blood tests, imaging techniques, skin biopsy, pulmonary function tests, and electrocardiogram & echocardiogram. Based on the indication, the global market is bifurcated into systemic scleroderma and localized scleroderma. The drug class segment is classified into prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase 5 inhibitors – PHA, immunosuppressors, analgesics, calcium channel blockers, and others.
Get More Insight before Buying@ : https://www.zionmarketresearch.com/inquiry/scleroderma-diagnostics-and-therapeutics-market
List of Key Players of Scleroderma Diagnostics and Therapeutics Market :
Boehringer Ingelheim International GmbH
arGentis Pharmaceuticals LLC
Bristol-Myers Squibb Company
F. Hoffman La-Roche Ltd.
Corbus Pharmaceuticals Holdings
Seattle Genetics Inc.
Kadmon Holdings Inc.
Emerald Health Pharmaceuticals
Prometic Life Sciences Inc.
Key questions answered in this report:
What are the growth rate forecast and market size for Scleroderma Diagnostics and Therapeutics Market ?
What are the key driving factors propelling the Scleroderma Diagnostics and Therapeutics Market forward?
What are the most important companies in the Scleroderma Diagnostics and Therapeutics Market Industry?
What segments does the Scleroderma Diagnostics and Therapeutics Market cover?
How can I receive a free copy of the Scleroderma Diagnostics and Therapeutics Market sample report and company profiles?
Market size value in 2021
USD 2232.5 Million
Revenue forecast in 2028
USD 4127.6 Million
CAGR of almost 9.2 % 2022-2028
2016 - 2021
2022 - 2028
By Product Type, By Application, and By End Use
Value (USD Billion), and Volume (Units)
Revenue in USD million/billion and CAGR from 2022 to 2028
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Bayer AG; Boehringer Ingelheim International GmbH, arGentis Pharmaceuticals, LLC, Celgene Corp., Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd., Corbus Pharmaceuticals Holdings, Seattle Genetics, Inc., Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, and Prometic Life Sciences, Inc.
Market growth drivers, restraints, opportunities, Porter's five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
In March 2021, Roche received approval for Actemra®/RoActemra® (tocilizumab) subcutaneous injection from the US Food and Drug Administration (FDA) for decreasing the rate of drop in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a chronic condition with few treatment options. The FDA has approved Actemra/RoActemra as the first biologic medication for the treatment of the condition.
In April 2020, Boehringer Ingelheim received approval from the European Commission for nintedanib for the treatment of people with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
North America is estimated to rule the market for scleroderma diagnostics and therapeutics.
Among the regions, North America is expected to dominate the global scleroderma diagnostics and therapeutics market. Major factors such as favorable reimbursement policies, heavy investment in R&D and drug development, and well-established healthcare infrastructure are boosting the growth of the market in this region. Additionally, the growing prevalence of the disease and technological advancement in the field of medical devices are also propelling the growth of the market in this region. Europe is anticipated to hold the second-most position in the market owing to an increase in initiatives and proactive awareness regarding the diagnostics for scleroderma. On the other hand, the market in Asia Pacific is likely to grow at the highest CAGR during the forecast period. This is majorly due to the wide and easy availability of generic & biosimilar immunosuppressants for the treatment of scleroderma.
Global Scleroderma Diagnostics and Therapeutics Market is segmented as follows:
Scleroderma Diagnostics and Therapeutics Market : By Diagnostic Test Type Outlook (2022-2028)
Pulmonary Function Tests
Electrocardiogram & Echocardiogram
Scleroderma Diagnostics and Therapeutics Market : By Indication Outlook (2022-2028)
Scleroderma Diagnostics and Therapeutics Market : By Drug Class Outlook (2022-2028)
Endothelin Receptor Antagonists
Phosphodiesterase 5 Inhibitors – PHA
Calcium Channel Blockers
Scleroderma Diagnostics and Therapeutics Market : By Region Outlook (2022-2028)
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East & Africa
Rest of Middle East & Africa
Press Release For Scleroderma Diagnostics and Therapeutics Market : https://www.zionmarketresearch.com/news/global-scleroderma-diagnostics-and-therapeutics-market
Browse Other Related Research Reports from Zion Market Research
Orthopedic Soft Tissue Repair Market - Global Industry Analysis: The global Orthopedic Soft Tissue Repair Market accrued earnings worth approximately 5.7 (USD Billion) in 2020 and is predicted to gain revenue of about 11.2 (USD Billion) by 2028, is set to record a CAGR of nearly 6.4% over the period from 2021 to 2028.
Surgical Drainage Devices Market - Global Industry Analysis: The global Surgical Drainage Devices Market accrued earnings worth approximately 1.12 (USD Billion) in 2020 and is predicted to gain revenue of about 3.20 (USD Billion) by 2028, is set to record a CAGR of nearly 5.7% over the period from 2021 to 2028.
Charcot-Marie-Tooth Disease Type I Market - Global Industry Analysis: The global charcot-marie-tooth disease type I market accounted for USD 480.72 in 2020 and is expected to reach USD 632.16 Million by 2028, growing at a CAGR of 3.5% from 2021 to 2028.
Browse through Zion Market Research's coverage of the Global Healthcare Industry
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Blog : https://zmrblog.com/ | https://www.marketbusinessinsights.com/
View original content:https://www.prnewswire.com/news-releases/at-9-2-cagr-scleroderma-diagnostics-and-therapeutics-market-size-to-hit-us-4124-6-million-globally-by-2028--industry-trends-share-growth-rate-value-analysis--forecast-report-by-zmr-301574005.html
SOURCE Zion Market Research